Semaglutide moved beyond standard obesity and diabetes endpoints as a small clinical trial reported lower heavy drinking days among individuals with alcohol use disorder and obesity. Investigators published the findings in The Lancet, describing once-weekly injections as a therapy that reduced heavy drinking days and altered alcohol consumption behavior. Additional evidence continued to strengthen the cardiovascular profile of GLP-1 receptor agonists through a systematic review and meta-analysis that examined more than 90,000 patients, reported by Anglia Ruskin University. For developers and payers, these data widen the clinical conversation around GLP-1 drugs—spanning behavior and cardiovascular outcomes—while also increasing competitive interest in multi-indication positioning.